Umifenovir, Drugs Monitor

(16 Dec 2020) Umifenovir- significant improvement in Clinical outcomes compared to KALETRA

December 17, 2020

Effect of Arbidol (Umifenovir) on COVID-19: a randomized controlled trial https://doi.org/10.1186/s12879-020-05698-w TRIAL REGISTRATION: IRCT20180725040596N2 , The mean age of patients was 56.6 (17.8) years and 56.2 (14.8) years in ARB and KALETRA groups, respectively. Majority of patients were male across… Continue reading "(16 Dec 2020) Umifenovir- significant improvement in Clinical outcomes compared to KALETRA"

(25 Oct 2020) Arbidol- showed beneficial effects on fever recovery, viral clearance and shorter hospital stay in males

October 31, 2020

Clinical features and efficacy of antiviral drug, Arbidol in 220 nonemergency COVID-19 patients from East-West-Lake Shelter Hospital in Wuhan: a retrospective case series https://doi.org/10.1186/s12985-020-01428-5 In the retrospective COVID-19 cohort, gender was one of the important factors affecting patient’s conditions. Arbidol… Continue reading "(25 Oct 2020) Arbidol- showed beneficial effects on fever recovery, viral clearance and shorter hospital stay in males"

(03 July 2020) Umifenovir-no evidence to support the use of umifenovir for improving patient-important outcomes

July 6, 2020

Efficacy and safety of umifenovir for coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis https://doi.org/10.1002/jmv.26256 A total of 12 studies with 1052 patients were included in final review studies. Compared with control group, umifenovir is associated with higher negative… Continue reading "(03 July 2020) Umifenovir-no evidence to support the use of umifenovir for improving patient-important outcomes"

(24 June 2020) Arbidol- Prophylactic arbidol proved to be protective against COVID-19 in health professionals

June 25, 2020

Effectiveness of Arbidol for COVID-19 Prevention in Health Professionals https://doi.org/10.3389/fpubh.2020.00249 A total of 164 subjects were included in this study, 82 cases in the infected group and 82 controls in the uninfected group, with a median age of 37 years,… Continue reading "(24 June 2020) Arbidol- Prophylactic arbidol proved to be protective against COVID-19 in health professionals"

(09 June 2020) Arbidol- combined with adjuvant therapy could normalize patient’s temperature faster

June 11, 2020

A study on clinical effect of Arbidol combined with adjuvant therapy on COVID-19 https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.26142 The study included 62 patients with COVID-19 admitted to the First Hospital of Jiaxing from January to March, 2020, and all patients were divided into the… Continue reading "(09 June 2020) Arbidol- combined with adjuvant therapy could normalize patient’s temperature faster"

(24 May 2020) Arbidol- Arbidol/IFN-α2b combination did not accelerate virus clearance

May 25, 2020

Arbidol/IFN-α2b Therapy for Patients With Corona Virus Disease 2019: A Retrospective Multicenter Cohort Study https://doi.org/10.1016/j.micinf.2020.05.012 This is a multicenter retrospective cohort study of patients with laboratory-confirmed COVID-19 infection pneumonia from 3 hospitals in Hubei and Guangdong province, 141 adults (aged… Continue reading "(24 May 2020) Arbidol- Arbidol/IFN-α2b combination did not accelerate virus clearance"

(16 May 2020) Arbidol-favorable clinical response when arbidol is combined with LPV/r

May 16, 2020

Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study. https://doi.org/10.1016/j.jinf.2020.03.002 In this retrospective cohort study, 16 patients received oral arbidol and LPV/r in the combination group and 17 received oral LPV/r only in… Continue reading "(16 May 2020) Arbidol-favorable clinical response when arbidol is combined with LPV/r"

(11 May 2020) Arbidol – arbidol and Lopinavir/ritonavir combination therapy shows no good

May 12, 2020

Observation of the efficacy and safety of lopinavir / ritonavir and abidor in the treatment of new coronavirus pneumonia http://rs.yiigle.com/yufabiao/1193931.htm This paper describes retrospective analysis of the clinical data of 178 patients diagnosed as COVID-19 , and divided into 59… Continue reading "(11 May 2020) Arbidol – arbidol and Lopinavir/ritonavir combination therapy shows no good"

(29 April 2020)- Umifenovir- did not shorten the negativity time of SARS-CoV-2 in non ICU patients

April 30, 2020

Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study https://doi.org/10.1016/j.cmi.2020.04.026 In a retrospective study, 81 COVID-19 patients were included, with 45 in the umifenovir group and 36 in the control group. Baseline… Continue reading "(29 April 2020)- Umifenovir- did not shorten the negativity time of SARS-CoV-2 in non ICU patients"

(14 April 2020)- Umifenovir (Arbidol)- shorter duration of positive RNA test

April 23, 2020

Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19 https://www.journalofinfection.com/article/S0163-4453(20)30188-2/pdf In the present study, the authors anayzed the efficacy and safety of lopinavir/ritonavir and arbidol monotherapy in patients with COVID-19. On day 14 after the admission, no viral load was… Continue reading "(14 April 2020)- Umifenovir (Arbidol)- shorter duration of positive RNA test"

Tag: Umifenovir